Back to search

Article

Miltefosine enhances infectivity of miltefosine-resistant <i>Leishmania infantum</i> by attenuating innate immune recognition

2021-02-25

Abstract excerpt

Miltefosine (MIL) is currently the only oral drug available to treat visceral leishmaniasis but its use as first-line monotherapy has been compromised by an increasing treatment failure. Despite the scarce number of resistant clinical isolates, MIL-resistance by mutations in a single aminophospholipid transporter gene can easily be selected in a laboratory environment. These mutations result in a reduced survival...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3d23b554-6847-56d7-9e3b-deb87991cd71
DOI
10.1101/2021.02.22.432409
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Miltefosine enhances infectivity of miltefosine-resistant <i>Leishmania infantum</i> by attenuating innate immune recognitionDOI 10.1101/2021.02.22.432409
Select a neighboring publication to make it the new centre.